Cuba encouraged by early trials of homegrown COVID-19 vaccine

Cuba's state-run biopharmaceutical corporation BioCubaFarma said preliminary data from late phase trials showed that the Soberana 2 vaccine candidate for COVID-19 had 62% efficacy with just two of its three doses, as reported Fidelity.

"In a few weeks we should have the results for the efficacy with three doses which we expect will be superior," said Vicente Vérez, director of the Finlay Vaccine Institute, which developed Soberana 2.

Several countries from have expressed an interest in buying Cuba's vaccines, and Iran started producing Soberana 2 earlier this year as part of late-phase trials.